Head to head
DSIP against MK-677
Two compounds taken at night for different reasons that get confused with each other, a sleep peptide with limited and inconsistent human evidence and a ghrelin receptor agonist whose sleep effect is secondary to what it is actually sold for. The compounding advisory committee voted against recommending DSIP in July 2026.
Column A
DSIPDelta Sleep-Inducing Peptide
A naturally occurring peptide studied for sleep, stress resilience, and pain, with limited and inconsistent human evidence.
Column B
MK-677Ibutamoren (oral ghrelin receptor agonist)
A non-peptide, orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Completed but did not pass Phase 3 for approval.
Side by side, on the facts we can check
| Attribute | DSIP | MK-677 |
|---|---|---|
| Category | Nootropic & CNS | Growth Hormone |
| FDA status | Not FDA-approved. PCAC voted against recommending it for compounding (July 2026) | Not FDA-approved (failed to gain approval after Phase 3) |
| Half-life | Short (minutes) | ~24 hours |
| Molecular weight | 848.9 Da | 624.8 Da |
| Mechanism | Proposed to modulate sleep-related neural activity and stress hormone regulation, though its exact receptor targets remain unclear. | Agonizes the ghrelin/GH secretagogue receptor (GHS-R1a), increasing GH and IGF-1 while also stimulating appetite. |
| Human studies cited | 0 | 3 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between DSIP and MK-677?
DSIP: A naturally occurring peptide studied for sleep, stress resilience, and pain, with limited and inconsistent human evidence. MK-677: A non-peptide, orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Completed but did not pass Phase 3 for approval.
Which has stronger research evidence, DSIP or MK-677?
This database does not grade compounds. It counts what was run in people: 0 of the 3 studies cited on the DSIP profile were human work, against 3 of 3 for MK-677. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are DSIP and MK-677 FDA-approved?
DSIP: Not FDA-approved. PCAC voted against recommending it for compounding (July 2026). MK-677: Not FDA-approved (failed to gain approval after Phase 3).
Related posts
Blog articles that cover DSIP or MK-677, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Research / Sep 8, 2026 / 9 minPeptides for Sleep: DSIP, Epitalon and Pinealon Against the Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Regulation / Sep 8, 2026 / 9 minFDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.